Bioorganic and Medicinal Chemistry Letters, Volume 49, 1 October 2021,
Despite the better understanding of the mechanisms underlying Alzheimer's Disease (AD) and launched clinical trials, no AD-modifying treatment based on a synthetic drug has been introduced for almost twenty years. The serotonin 5-HT6 and 5-HT7 receptors turned out to be promising biological targets for modulation of central nervous system dysfunctions including cognitive impairment. Within this paper, we evaluate the pharmacological potency of both, 5-HT6R and 5-HT7R, agents in search for novel AD treatment. An overview of chemical structures of the 5-HTRs ligands with simultaneous procognitive action which have undergone preclinical and clinical studies within the last 10 years has been performed.
5-HT -antagonist 7; 5-HT R Antagonist 6; Alzheimer Disease; Alzheimer's Disease; Animal; Animals; Chemistry; Cognitive Impairments; Human; Humans; Metabolism; Nootropic Agent; Nootropic Agents; Procognitive Activity; Receptors, Serotonin; Serotonin 6 Receptor; Serotonin 7 Receptor; Serotonin Agonist; Serotonin Antagonist; Serotonin Antagonists; Serotonin Receptor; Serotonin Receptor Agonists; Serotonin Receptors; Global